• Synergistic Apoptosis and Pyroptosis via Hyperthermia-Cispla

  2026-04-30

  The referenced study reveals a novel mechanism by which combined hyperthermia and cisplatin therapy enhances both apoptosis and pyroptosis in cancer cells through caspase-8 accumulation and activation. These findings clarify the interplay between the caspase signaling pathway and polyubiquitination processes, suggesting new avenues for optimizing cell death-based cancer treatments.

• TCF25 Enhances Lysosomal Acidification and Cell Death in Glu

  2026-04-30

  Ren et al. (2025) identify TCF25 as a nutrient sensor that orchestrates metabolic adaptation and lysosome-dependent cell death during glucose starvation by enhancing lysosomal acidification through V-ATPase activation. This work offers mechanistic insight into nutrient stress responses and highlights potential targets for metabolic and ischemic disease intervention.

• Sodium dicloxacillin monohydrate: Reliable Solutions for MSS

  2026-04-29

  This authoritative guide addresses common laboratory challenges in cell viability, proliferation, and cytotoxicity assays involving Gram-positive bacteria. Leveraging validated data and best practices, we demonstrate how Sodium dicloxacillin monohydrate (SKU C8716) from APExBIO ensures reproducibility, sensitivity, and workflow compatibility for MSSA research.

• AT-406 (SM-406): Precision Modulation of Apoptosis in Cancer

  2026-04-29

  Discover how AT-406 (SM-406) enables nuanced control of apoptosis pathways in cancer cells, with a focus on practical assay optimization and mechanistic insights. This article uniquely links structural findings to real-world protocol decisions.

• Everolimus (RAD001) in Cancer Research: Protocols and Pitfal

  2026-04-28

  Everolimus (RAD001) is a gold-standard mTOR inhibitor that empowers cancer researchers with robust, reproducible data in proliferation and apoptosis assays. This article distills experimental wisdom, advanced use-cases, and troubleshooting guidance to maximize the reliability and translational power of your Everolimus-based workflows.

• SN-38 Inhibits FUBP1–FUSE Binding: Mechanistic Insights for

  2026-04-28

  This study establishes that SN-38, the active metabolite of irinotecan and a potent DNA topoisomerase I inhibitor, directly disrupts the binding of the oncogenic transcriptional regulator FUBP1 to its DNA target sequence FUSE. These findings reveal a novel, dual-action mechanism that could inform advanced colon cancer research and future therapeutic strategies.

• KIR2.1 Inhibition Restricts PASMC Proliferation and Migratio

  2026-04-27

  This study demonstrates that inhibition of the Kir2.1 potassium channel suppresses proliferation and migration of pulmonary artery smooth muscle cells (PASMCs), key processes in pulmonary vascular remodeling and hypertension. By elucidating the Kir2.1-TGF-β1/SMAD2/3 axis, the research provides a mechanistic foundation for targeting ion channels in pulmonary hypertension therapy.

• PF-04971729 (Ertugliflozin): Precision Tools for Diabetes Re

  2026-04-27

  PF-04971729 (Ertugliflozin) delivers unrivaled SGLT2 selectivity and translational relevance for diabetes mellitus and renal glucose transport studies. This guide unpacks actionable workflows, troubleshooting strategies, and evidence-based protocol upgrades for researchers leveraging APExBIO’s high-purity compound.

• Scenario-Driven Solutions with Pomalidomide (CC-4047) in Hem

  2026-04-26

  This article provides a scenario-based, evidence-driven guide for leveraging Pomalidomide (CC-4047) (SKU A4212) in hematological malignancy research. Drawing on current literature and practical lab experience, it addresses key workflow challenges in cell viability, cytokine modulation, and erythroid differentiation. Designed for biomedical researchers and lab technicians, it demonstrates how SKU A4212 from APExBIO streamlines assay reproducibility and data reliability.

• Cycloheximide: Precision Protein Biosynthesis Inhibitor in A

  2026-04-25

  Cycloheximide, a gold-standard protein biosynthesis inhibitor from APExBIO, delivers acute, reversible control over translational elongation in eukaryotic cells. Its robust performance empowers advanced apoptosis assays, protein turnover studies, and hypoxic injury models—enabling mechanistic clarity and reproducibility across diverse research workflows.

• STING Agonist-1: Precision Tools for B Cell-Driven Immunity

  2026-04-24

  Explore how STING agonist-1, a high-purity small molecule from APExBIO, is advancing translational research by enabling targeted activation of the STING pathway. Leveraging breakthrough mechanistic insights from esophageal squamous cell carcinoma (ESCC), this thought-leadership article provides translational researchers with actionable strategies for dissecting IRF4-mediated B cell activation, optimizing model systems, and accelerating biomarker discovery—surpassing the scope of conventional product literature.

• Zosuquidar (LY335979) 3HCl: Strategic P-gp Inhibition in Tra

  2026-04-24

  This thought-leadership article explores the mechanistic and strategic value of Zosuquidar (LY335979) 3HCl as a next-generation tool for overcoming multidrug resistance (MDR) in cancer research. Integrating recent insights into P-glycoprotein efflux pump inhibition, the translational landscape, and evolving experimental best practices, it offers nuanced guidance for researchers seeking robust, reproducible results in preclinical and early clinical contexts. The discussion bridges bench-to-bedside considerations, incorporates lessons from recent transporter-focused pharmacokinetic studies, and provides actionable protocol parameters for MDR reversal. Differentiated from standard product descriptions, this piece contextualizes Zosuquidar within emerging cross-domain themes and future research frontiers.

• Anlotinib Hydrochloride Inhibits Angiogenesis via VEGFR2, PD

  2026-04-23

  This study demonstrates that anlotinib hydrochloride, a multi-target tyrosine kinase inhibitor, robustly suppresses angiogenesis by simultaneously inhibiting VEGFR2, PDGFRβ, and FGFR1 activation. The findings highlight its superior efficacy compared to established TKIs in inhibiting endothelial cell migration, tube formation, and neovessel development, underscoring its value as an experimental tool in cancer and angiogenesis research.

• Angiotensin Peptides Enhance SARS-CoV-2 Spike–AXL Binding

  2026-04-23

  This study demonstrates that naturally occurring angiotensin peptides, including fragments such as Angiotensin 1/2 (5-7), significantly enhance the binding of the SARS-CoV-2 spike protein to the AXL receptor. These findings extend our understanding of the intersection between renin-angiotensin system peptides and viral pathogenesis, with implications for both cardiovascular research and COVID-19 biology.

• Gefitinib (ZD1839): EGFR Inhibition in Advanced Tumor Models

  2026-04-22

  Gefitinib (ZD1839) empowers researchers to unravel EGFR-driven signaling, drug resistance, and apoptosis induction in physiologically relevant assembloid models. This article details evidence-backed workflows, advanced troubleshooting, and translational strategies for maximizing impact in non-small-cell lung and gastric cancer research.

16547 records 1/1104 page Next 12345 下5页 Last page